7 results about "Immunologic Competence" patented technology

The invention belongs to the technical field of active peptide preparation, and particularly relates to an active collagen peptide with an immunoregulation function and a preparation method and application thereof. The active collagen peptide with an immunoregulation function is prepared by using a method of performing composite enzymolysis and separating and collecting specified collection liquid by using a chromatographic column, and a new thought is provided for improving the immunity; the prepared active collagen peptide can significantly improve the proliferative activity, phagocytic ability and NO secretion amount of RAW264.7 cells and change the cell morphology, has an important regulation effect on immune balance recovery of immunosuppression model mice, and can regulate the problem of low immunologic function of mice induced by cyclophosphamide, regulate immune balance and improve the body immunity.

A method for determining immune competence against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) includes obtaining a blood sample from a subject in need thereof, detecting, in the blood sample, levels of binding antibodies against SARS-CoV-2 spike S1 protein and its receptor binding domain (RBD), and calculating a weighted value using a regression model. Another method for determining immune competence against SARS-CoV-2 is also disclosed.

The present disclosure provides a biomarker for predicting and diagnosing the pathology, the prognosis, and the therapeutic effect of a T-cell-related disease. More specifically, the present disclosure provides: a marker that is a binding-type soluble PD-L1 (bsPD-L1 / sPD-L1 with PD-1-binding capacity) for use in predicting the pathology, the prognosis, and the therapeutic effect of cancer and / or T-cell related diseases, as well as a factor, an agent, an element, or a composition that interacts with the marker; a factor that interacts with an agent, an element, or a composition for predicting the pathology, the prognosis, and the therapeutic effect of T-cell related diseases or with a host T-cell immune marker, the factor including factors that interact with at least one matrix metalloproeinase (MMP / matrix metalloproteinase) in a group A; and (2) a combination of a condition diagnostic marker and a factor that interacts therewith.

The invention belongs to the technical field of biological medicine, discloses application of an anti-tumor nano-drug with a radiotherapy sensitization effect, and particularly discloses application of azodiisobutyronitrile in preparation of a sensitizer, preparation of an anti-tumor drug with a sensitization effect or preparation of an anti-tumor drug carrier with a sensitization effect. According to the invention, azobisisobutyronitrile is used for preparing the sensitizer (X-ray radiotherapy sensitizer) for the first time, and Pluronic F127 (F127) is used for encapsulating azobisisobutyronitrile to obtain the radiotherapy sensitizer AIBN-coated F127. After X-ray irradiation, AIBN (at) F127 taken by tumor cells is activated, azo free radicals are generated in situ, and a strong anti-cancer effect is achieved. The TNBC cells can be effectively killed, so that the stronger anti-tumor immunocompetence is mobilized.

Methods and compositions for promoting donor - specific tolerance and immune competence in a recipient of a solid organ graft, which are effected by: implanting an allogeneic solid organ in a recipient in need of a solid organ transplant, and further comprising surgically implanting a tissue - engineered allogeneic cultured post - natal thymic tissue product in the recipient of the solid organ from the donor. A method for producing an allogeneic cultured post - natal thymic tissue - derived product suitable for implantation into a human; a method for culturing an allogeneic cultured post - natal thymic tissue - derived product suitable for implantation into a human; and a method for using an allogeneic cultured post - natal thymic tissue - derived product by implanting into a human subject.

Systems and methods are provided for transfecting immune competent cells with RNA at high efficiency and viability.